NFKB1 and cystic fibrosis: Anti-inflammatory responses to iPR treatment have been documented in Chinese hamster ovary (CHO) cells where they are mediated through binding to adenosine A3 receptor [48,49] and in cystic fibrosis cell lines via inhibition of NFκB and STAT3 pathways [50].